Atea Presents Results of AT-527 in P-I Study for COVID 19 at CROI

 Atea Presents Results of AT-527 in P-I Study for COVID 19 at CROI

Atea Presents Results of AT-527 in P-I Study for COVID 19 at CROI

Shots:

  • The P-I study involves assessing the safety and PK of AT-527 (550 mg, q2, BID) vs PBO for 5 days in 20 healthy volunteers in a ratio (1:1) to treat COVID-19
  • The result showed rapid attainment of steady state levels within 2days of dosing, predicted lung AT-9010 levels were consistently above the EC90 level of 0.5 µM for in vitro inhibition
  • AT-527 is an orally administered, direct-acting antiviral agent, currently being evaluated in a P-II study for hospitalized patients with moderate COVID-19 and P-II virology study in patients with mild or mod. COVID-19 in an outpatient setting

Click here ­to­ read full press release/ article | Ref: Atea Pharma | Image: Atea Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post